A Study Evaluating Botulinum Toxin Type A in Subjects With Postherpetic Neuralgia
Phase 2
Completed
- Conditions
- Postherpetic Neuralgia
- Registration Number
- NCT00168441
- Lead Sponsor
- Allergan
- Brief Summary
4-month study including a 30-day baseline phase
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 117
Inclusion Criteria
- Postherpetic neuralgia for more than 3 months after the healing of a herpes zoster skin rash.
Exclusion Criteria
- Previous use of botulinum toxin of any serotype or immunization to any botulinum toxin serotype.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Pain score
- Secondary Outcome Measures
Name Time Method Various Quality of Life questionnaires Reduction in area of pain/allodynia
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which botulinum toxin type A alleviates postherpetic neuralgia pain?
How does botulinum toxin type A compare to gabapentinoids in treating postherpetic neuralgia?
Are there specific biomarkers that predict response to botulinum toxin type A in postherpetic neuralgia patients?
What adverse events are associated with botulinum toxin type A for postherpetic neuralgia and how are they managed?
What are the current combination therapies involving botulinum toxin type A for neuropathic pain management?